Captrust Financial Advisors Monopar Therapeutics Transaction History

Captrust Financial Advisors

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 16, 2022	BUY	$1.85 - $2.72 $314 - $462	170 New	170 $0
Q1 2022 May 16, 2022	SELL	$2.5 - $3.62 $425 - $615	-170 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$4.36 - $7.49 $741 - $1,273	170 New	170 $1,000
Q3 2020 Nov 17, 2020	SELL	$4.93 - $8.15 $838 - $1,385	-170 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$6.4 - $9.5 $1,088 - $1,615	170 New	170 $1,000

Ticker MNPR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,725,800
Market Cap $316M
Description
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe ...

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

Stay updated on Captrust Financial Advisors with notifications on news.